Conventional infection surveillance misses hospital transmission events that whole-genome sequencing catches, and now the field’s most visible accreditor has said so publicly. UPMC Presbyterian Hospital in Pittsburgh received the Joint Commission’s John M. Eisenberg Award for Local Level Innovation in Patient Safety and Quality for its prospective bacterial whole-genome sequencing (WGS) program, titled “Real-Time Genomic Surveillance for Outbreak Detection.” The practical consequence for infection prevention teams is straightforward: the Joint Commission’s endorsement gives hospital administrators a credibility anchor when weighing the operational cost of standing up a sequencing program.
The distinction the award draws is between reactive and prospective use of WGS. Standard surveillance, including definitions used by the National Healthcare Safety Network, misses transmission events that WGS identifies, according to published work co-led by Dr. Alex Sundermann, a member of NGD Infection Prevention’s Scientific Advisory Board. Running sequencing on incoming bacterial isolates as a routine matter, rather than only after an outbreak is suspected, lets infection prevention teams trace transmission chains while they are still interruptible. The UPMC team also reported that the program produced net cost savings above the expense of WGS itself, alongside shorter lengths of stay, though the source does not specify the dollar figures.
NGD Infection Prevention, the Cambridge, Massachusetts company whose automated sequencing platform is built around this model, stands to gain from the recognition. Its NGD200 system processes 48 bacterial samples overnight without a specialized technician, and its EpiAssist software automates root-cause identification so infection prevention staff can move directly to intervention rather than spending time on bioinformatics. The award is not a product endorsement, but it validates the underlying method at a time when NGD says it is beginning broad deployment of the platform.
The watch point for clinical operations teams is whether the Joint Commission’s recognition accelerates adoption beyond academic medical centers. UPMC Presbyterian is a large, well-resourced institution; the question is whether the cost-savings data Sundermann’s group reported holds at community hospitals with smaller laboratory footprints and lower sample volumes, where the economics of overnight batch sequencing look quite different.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
